lundi 13 février 2017

Onco Actu du 13 février 2017

1. Biologie

Scientists identify aggressive pancreatic cancer cells and their vulnerability [MD Anderson]

3.1.1 Tabac - e-cigs

Australia’s looming e-cigarette ban robs smokers of a chance to quit [The Conversation]

Kids who live with e-cigarette users may think smoking is okay [Reuters]

4. Dépistage, diagnostic et pronostic

Pancreatic cancer biomarker bolsters nanoparticle-based diagnostic [C&EN]

‘Magic’ blood test could make bone marrow transplants for blood cancer safer [Cancer Research UK]

4.9 Dép., diag. & prono. - Sein

Women Who Have A False Positive Screening Mammogram More Likely to Delay Next Screen [AACR]

5. Traitements

Three-Drug Combination Extends Survival for Patients with Multiple Myeloma [NCI]

Memorial Sloan Kettering Researchers Publish Roadmap to Precision Oncology [Memorial Sloan Kettering]

How to stop brain cancer—with rabies [Science]

Amid flurry of new cancer drugs, how many offer real benefits? [CNN]

Last Month in Oncology with Dr. Bishal Gyawali: January 2017 [ecancernews]

New method reduces adverse effects of rectal cancer treatment [Karolinska Institutet]

5.10 Traitements - Essais

Tracon slips as brain cancer trial misses the mark [FierceBiotech]

TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma [Tracon]

5.12.3 Immunothérapies-combinaisons

Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung [Boehringer Ingelheim]

5.12.5 Immunothérapies - Pharma

Playing catch-up, Regeneron and Sanofi push ahead on pivotal PD-1 cancer studies [EndPoints]

5.2 Pharma

Will pharma use a tax break to create new jobs? That’s not what happened last time [STAT]

5.2.2 Pharma - Fusions & Acquisitions

Cancer drugmaker Tesaro weighs its options as wannabe buyers come running [FiercePharma]

5.2.3 Pharma - économie

Seattle Genetics pens $2B pact to bag Immunomedics’ drug [FierceBiotech]

Seattle Genetics Puts Up $250M for Immunomedics Cancer Drug Rights [Xconomy]

Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors [Seattle Genetics]

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

What if, rather than being too stringent about drug approval, the FDA is not being stringent enough? [Respectful Insolence]

Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation [Xconomy]

WHO director issues thinly veiled rebuke of FDA critics [STAT]

5.3.4 Traitements - AMM (FDA, EMA)

Over 1,000 studies now recorded in EU register of post-authorisation studies [EMA]

5.4 Traitements - Economie

A Call For Academic Drug Companies [In the Pipeline]

Cancer drug prices must come down, say leading research institutes [The Guardian]

Academics call time on $100,000 cancer drugs [Reuters]

6. Lutte contre les cancers

NHS cancer treatment target in England missed for third consecutive year [Cancer Research UK]

6.1 Observation

Children’s cancer survival continues to increase [Cancer Research UK]

6.10 Politiques

Cancer drugs may be delayed after Brexit, say experts [BBC News]

6.11 Patients

The day two men talking about cancer on the radio made the nation stop [The Guardian]

6.3 Associations/Fondations

Cancer Research UK announces inaugural Grand Challenge teams to answer the biggest questions in cancer [Cancer Research UK]

3 of the toughest questions in cancer and more than £70 million to solve them [Cancer Research UK]

U.K. cancer charity awards £71 million for four major research challenges [Science]

6.6 Publications

Draft display guidelines for iDs in articles open for comment [ORCID blogs]

6.8 Communication

A ‘trick’ to finding breast cancer goes viral on Facebook–here’s what was missing from the message [healthNewsReview]

6.9 Controverses

Dana-Farber must rethink its decision to keep its fundraiser at Mar-a-Lago [STAT]